24 results on '"Wasser MNJM"'
Search Results
2. Applicability and reproducibility of the CPAT-grading system for pancreas allograft thrombosis
- Author
-
Simonis, SA, primary, de Kok, BM, additional, Korving, JC, additional, Kopp, WH, additional, Baranski, AG, additional, Huurman, VAL, additional, Wasser, MNJM, additional, van der Boog, PJM, additional, and Braat, AE, additional
- Published
- 2021
- Full Text
- View/download PDF
3. Consequences of CT colonography in stenosing colorectal cancer
- Author
-
Huisman, JF, primary, Leicher, LW, additional, de Boer, E, additional, van Westreenen, HL, additional, de Groot, JW, additional, Holman, FA, additional, van de Meeberg, PC, additional, Sallevelt, PEJM, additional, Peeters, KCMJ, additional, Wasser, MNJM, additional, Vasen, HFA, additional, and de Vos tot Nederveen Cappel, WH, additional
- Published
- 2016
- Full Text
- View/download PDF
4. Abstract P1-06-04: The predictive value of tumor-stroma ratio for radiological and pathological response to neoadjuvant chemotherapy in breast cancer (BC): A Dutch breast cancer trialists’ group (BOOG) side-study
- Author
-
Dekker, TJA, primary, Charehbili, A, additional, Smit, VTHBM, additional, Wasser, MNJM, additional, Heijns, JB, additional, van Warmerdam, LJ, additional, Kessels, L, additional, Dercksen, W, additional, Pepels, M, additional, Maartense, E, additional, van Laarhoven, HWM, additional, Vriens, B, additional, Meershoek-Klein Kranenbarg, E, additional, van de Velde, CJH, additional, Liefers, G-J, additional, Nortier, HWR, additional, Tollenaar, RAEM, additional, Mesker, WE, additional, and Kroep, JR, additional
- Published
- 2013
- Full Text
- View/download PDF
5. Gadobenate dimeglumine-enhanced MR angiography of the adbominal aorta and renal arteries
- Author
-
Kroencke, TJ, Wasser, MNJM, Pattynama, Peter, Barentsz, JO, Grabbe, E, Marchal, G, Knopp, MV, Schneider, G, Bonomo, L, Pennell, DJ, del Maschio, A, Hentrich, H-R, Daprà, M, Kirchin, MA, Spinazzi, A, Taupitz, M, Hamm, B, and Radiology & Nuclear Medicine
- Published
- 2002
6. Scan optimization of gadolinium contrast-enhanced three-dimensional MRA of peripheral arteries with multiple bolus injections and in-vitro validation of stenosis quantification
- Author
-
Westenberg, JJM, Wasser, MNJM, van der Geest, RJ (Rob), Pattynama, Peter, de Roos, A, Vanderschoot, J, Reiber, JHC (Johan), Cardiothoracic Surgery, Radiology & Nuclear Medicine, and Cardiology
- Published
- 1999
7. Stenosis quantification from post-stenotic signal loss in phase-contrast MRA datasets of flow phantoms and renal arteries
- Author
-
Westenberg, JJM, van der Geest, RJ (Rob), Wasser, MNJM, Doornbos, J, Pattynama, Peter, de Roos, A, Vanderschoot, J, Reiber, JHC (Johan), Cardiothoracic Surgery, Radiology & Nuclear Medicine, and Cardiology
- Published
- 1999
8. Gadolinium-enhanced three-dimensional MRA of peripheral arteries with multiple bolus injections: scan optimization in-vitro and in-vivo
- Author
-
Westenberg, JJM, Wasser, MNJM, van der Geest, RJ (Rob), Pattynama, Peter, de Roos, A, Vanderschoot, J, Reiber, JHC (Johan), Cardiothoracic Surgery, Radiology & Nuclear Medicine, and Cardiology
- Published
- 1999
9. Niet-conventionele beeldvormende technieken bij inflammatoire darmziekten
- Author
-
Wasser, MNJM, Stoker, J, van Hogezand, RA, Griffioen, G, and Radiology & Nuclear Medicine
- Published
- 1998
10. Abstract PD07-06: NEO-ZOTAC: Toxicity data of a phase III randomized trial with NEOadjuvant chemotherapy (TAC) with or without ZOledronic acid (ZA) for patients with HER2-negative large resectable or locally advanced breast cancer (BC)
- Author
-
van de Ven, S, primary, Liefers, G-j, additional, Putter, H, additional, van Warmerdam, LJ, additional, Kessels, LW, additional, Dercksen, W, additional, Pepels, MJ, additional, Maartense, E, additional, van Laarhoven, HWM, additional, Vriens, B, additional, Smit, VTHBM, additional, Wasser, MNJM, additional, Meershoek-Klein, Kranenbarg EM, additional, van Leeuwen-Stok, E, additional, van de Velde, CJH, additional, Nortier, JWR, additional, and Kroep, JR, additional
- Published
- 2012
- Full Text
- View/download PDF
11. Thrombus detection using a Tc-99m labeled antifibrin monoclonal antibody (MgAb) experiments in vitro and in animals
- Author
-
Wasser, MNJM, primary, Pauwels, EKJ, additional, and Nieuwenhuizen, W, additional
- Published
- 1990
- Full Text
- View/download PDF
12. Vascularization of head and neck paragangliomas: Comparison of three MR angiographic techniques with digital subtraction angiography
- Author
-
Den Berg, R., Wasser, Mnjm, Gils, Apg, Mey, Agl, Hermans, J., and Mark van Buchem
13. Retroperitoneum revisited: a review of radiological literature and updated concept of retroperitoneal fascial anatomy with imaging features and correlating anatomy.
- Author
-
Boekestijn B, Wasser MNJM, Mieog JSD, and DeRuiter MC
- Subjects
- Humans, Retroperitoneal Space anatomy & histology, Retroperitoneal Space diagnostic imaging, Tomography, X-Ray Computed, Fascia anatomy & histology, Fascia diagnostic imaging
- Abstract
Purpose: Spread of disease in the retroperitoneum is dictated by the complex anatomy of retroperitoneal fasciae and is still incompletely understood. Conflicting reports have led to insufficient and incorrect anatomical concepts in radiological literature., Methods: This review will discuss previous concepts prevalent in radiological literature and their shortcomings will be highlighted. New insights from recent anatomical and embryological research, together with imaging examples, will be used to clarify patterns of disease spread in the retroperitoneum that remain unexplained by these concepts., Results: The fusion fascia and the renal fascia in particular give rise to planes and spaces that act as vectors for spread of disease in the retroperitoneum. Some of these planes and structures, such as the caudal extension of the renal fascia, have previously not been described in radiological literature., Conclusion: New insights, including the various fasciae, potential spaces and planes, are incorporated into an updated combined retroperitoneal fascial concept., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
14. The Added Value of Blood Glucose Monitoring in High-Risk Individuals Undergoing Pancreatic Cancer Surveillance.
- Author
-
Bogdanski AM, Onnekink AM, Inderson A, Boekestijn B, Bonsing BA, Vasen HFA, van Hooft JE, Boonstra JJ, Mieog JSD, Wasser MNJM, Feshtali S, Potjer TP, Klatte DCF, and van Leerdam ME
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Cyclin-Dependent Kinase Inhibitor p16, Diabetes Mellitus blood, Diabetes Mellitus diagnosis, Diabetes Mellitus epidemiology, Risk Factors, Blood Glucose Self-Monitoring methods, Early Detection of Cancer methods, ROC Curve, Risk Assessment methods, Pancreatic Neoplasms blood, Pancreatic Neoplasms diagnosis, Blood Glucose metabolism, Blood Glucose analysis, Carcinoma, Pancreatic Ductal blood, Carcinoma, Pancreatic Ductal diagnosis
- Abstract
Objectives: The study aimed to investigate the added value of blood glucose monitoring in high-risk individuals (HRIs) participating in pancreatic cancer surveillance., Materials and Methods: High-risk individuals with a CDKN2A/p16 germline pathogenic variant participating in pancreatic cancer surveillance were included in this study. Multivariable logistic regression was performed to assess the relationship between new-onset diabetes (NOD) and pancreatic ductal adenocarcinoma (PDAC). To quantify the diagnostic performance of NOD as a marker for PDAC, receiver operating characteristic curve with area under the curve was computed., Results: In total, 220 HRIs were included between 2000 and 2019. Median age was 61 (interquartile range. 53-71) years and 62.7% of participants were female. During the study period, 26 (11.8%) HRIs developed NOD, of whom 5 (19.2%) later developed PDAC. The other 23 (82.1%) PDAC cases remained NOD-free. Multivariable analysis showed no statistically significant relationship between NOD and PDAC (odds ratio, 1.21; 95% confidence interval, 0.39-3.78) and 4 of 5 PDAC cases seemed to have NOD within 3 months before diagnosis. Furthermore, NOD did not differentiate between HRIs with and without PDAC (area under the curve, 0.54; 95% confidence interval, 0.46-0.61)., Conclusions: In this study, we found no added value for longitudinal glucose monitoring in CDKN2A pathogenic variant carriers participating in an imaging-based pancreatic cancer surveillance program., Competing Interests: The authors declare no conflict of interest., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
15. Aspects and outcomes of surveillance for individuals at high-risk of pancreatic cancer.
- Author
-
Bogdanski AM, van Hooft JE, Boekestijn B, Bonsing BA, Wasser MNJM, Klatte DCF, and van Leerdam ME
- Subjects
- Humans, Population Surveillance, Risk Factors, Prognosis, Incidence, Pancreatic Neoplasms epidemiology, Pancreatic Neoplasms diagnosis, Carcinoma, Pancreatic Ductal epidemiology, Carcinoma, Pancreatic Ductal diagnosis, Early Detection of Cancer methods
- Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths and is associated with a poor prognosis. The majority of these cancers are detected at a late stage, contributing to the bad prognosis. This underscores the need for novel, enhanced early detection strategies to improve the outcomes. While population-based screening is not recommended due to the relatively low incidence of PDAC, surveillance is recommended for individuals at high risk for PDAC due to their increased incidence of the disease. However, the outcomes of pancreatic cancer surveillance in high-risk individuals are not sorted out yet. In this review, we will address the identification of individuals at high risk for PDAC, discuss the objectives and targets of surveillance, outline how surveillance programs are organized, summarize the outcomes of high-risk individuals undergoing pancreatic cancer surveillance, and conclude with a future perspective on pancreatic cancer surveillance and novel developments., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
16. 89 Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study.
- Author
-
Linders DGJ, Deken MM, van Dam MA, Wasser MNJM, Voormolen EMC, Kroep JR, van Dongen GAMS, Vugts D, Oosterkamp HM, Straver ME, van de Velde CJH, Cohen D, Dibbets-Schneider P, van Velden FHP, Pereira Arias-Bouda LM, Vahrmeijer AL, Liefers GJ, de Geus-Oei LF, and Hilling DE
- Abstract
Background: Approximately 20% of invasive ductal breast malignancies are human epidermal growth factor receptor 2 (HER2)-positive. These patients receive neoadjuvant systemic therapy (NAT) including HER2-targeting therapies. Up to 65% of patients achieve a pathological complete response (pCR). These patients might not have needed surgery. However, accurate preoperative identification of a pCR remains challenging. A radiologic complete response (rCR) on MRI corresponds to a pCR in only 73% of patients. The current feasibility study investigates if HER2-targeted PET/CT-imaging using Zirconium-89 (
89 Zr)-radiolabeled trastuzumab can be used for more accurate NAT response evaluation., Methods: HER2-positive breast cancer patients scheduled to undergo NAT and subsequent surgery received a89 Zr-trastuzumab PET/CT both before (PET/CT-1) and after (PET/CT-2) NAT. Qualitative and quantitative response evaluation was performed., Results: Six patients were enrolled. All primary tumors could be identified on PET/CT-1. Four patients had a pCR and two a pathological partial response (pPR) in the primary tumor. Qualitative assessment of PET/CT resulted in an accuracy of 66.7%, compared to 83.3% of the standard-of-care MRI. Quantitative assessment showed a difference between the SUVR on PET/CT-1 and PET/CT-2 (ΔSUVR ) in patients with a pPR and pCR of -48% and -90% ( p = 0.133), respectively. The difference in tumor-to-blood ratio on PET/CT-1 and PET/CT-2 (ΔTBR) in patients with pPR and pCR was -79% and -94% ( p = 0.133), respectively. Three patients had metastatic lymph nodes at diagnosis that were all identified on PET/CT-1. All three patients achieved a nodal pCR. Qualitative assessment of the lymph nodes with PET/CT resulted in an accuracy of 66.7%, compared to 50% of the MRI., Conclusions: NAT response evaluation using89 Zr-trastuzumab PET/CT is feasible. In the current study, qualitative assessment of the PET/CT images is not superior to standard-of-care MRI. Our results suggest that quantitative assessment of89 Zr-trastuzumab PET/CT has potential for a more accurate response evaluation of the primary tumor after NAT in HER2-positive breast cancer.- Published
- 2023
- Full Text
- View/download PDF
17. Surveillance for Pancreatic Cancer in High-Risk Individuals Leads to Improved Outcomes: A Propensity Score-Matched Analysis.
- Author
-
Klatte DCF, Boekestijn B, Onnekink AM, Dekker FW, van der Geest LG, Wasser MNJM, Feshtali S, Mieog JSD, Luelmo SAC, Morreau H, Potjer TP, Inderson A, Boonstra JJ, Vasen HFA, van Hooft JE, Bonsing BA, and van Leerdam ME
- Subjects
- Humans, Propensity Score, Prognosis, Retrospective Studies, Pancreatic Neoplasms, Pancreatic Neoplasms diagnosis, Pancreatic Neoplasms epidemiology, Pancreatic Neoplasms genetics, Carcinoma, Pancreatic Ductal genetics, Carcinoma, Pancreatic Ductal therapy
- Abstract
Background & Aims: Recent pancreatic cancer surveillance programs of high-risk individuals have reported improved outcomes. This study assessed to what extent outcomes of pancreatic ductal adenocarcinoma (PDAC) in patients with a CDKN2A/p16 pathogenic variant diagnosed under surveillance are better as compared with patients with PDAC diagnosed outside surveillance., Methods: In a propensity score matched cohort using data from the Netherlands Cancer Registry, we compared resectability, stage, and survival between patients diagnosed under surveillance with non-surveillance patients with PDAC. Survival analyses were adjusted for potential effects of lead time., Results: Between January 2000 and December 2020, 43,762 patients with PDAC were identified from the Netherlands Cancer Registry. Thirty-one patients with PDAC under surveillance were matched in a 1:5 ratio with 155 non-surveillance patients based on age at diagnosis, sex, year of diagnosis, and tumor location. Outside surveillance, 5.8% of the patients had stage I cancer, as compared with 38.7% of surveillance patients with PDAC (odds ratio [OR], 0.09; 95% confidence interval [CI], 0.04-0.19). In total, 18.7% of non-surveillance patients vs 71.0% of surveillance patients underwent a surgical resection (OR, 10.62; 95% CI, 4.56-26.63). Patients in surveillance had a better prognosis, reflected by a 5-year survival of 32.4% and a median overall survival of 26.8 months vs 4.3% 5-year survival and 5.2 months median overall survival in non-surveillance patients (hazard ratio, 0.31; 95% CI 0.19-0.50). For all adjusted lead times, survival remained significantly longer in surveillance patients than in non-surveillance patients., Conclusion: Surveillance for PDAC in carriers of a CDKN2A/p16 pathogenic variant results in earlier detection, increased resectability, and improved survival as compared with non-surveillance patients with PDAC., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
18. Cost-effectiveness of pancreas surveillance: The CDKN2A-p16-Leiden cohort.
- Author
-
Ibrahim IS, Vasen HFA, Wasser MNJM, Feshtali S, Bonsing BA, Morreau H, Inderson A, de Vos Tot Nederveen Cappel WH, and van den Hout WB
- Subjects
- Humans, Cost-Benefit Analysis, Pancreas pathology, Cyclin-Dependent Kinase Inhibitor p16 genetics, Pancreatic Neoplasms, Pancreatic Neoplasms diagnosis, Pancreatic Neoplasms epidemiology, Pancreatic Neoplasms genetics, Carcinoma, Pancreatic Ductal diagnosis, Carcinoma, Pancreatic Ductal genetics, Carcinoma, Pancreatic Ductal surgery
- Abstract
Background: CDKN2A-p16-Leiden mutation carriers have a high lifetime risk of developing pancreatic ductal adenocarcinoma (PDAC), with very poor survival. Surveillance may improve prognosis., Objective: To assess the cost-effectiveness of surveillance, as compared to no surveillance., Methods: In 2000, a surveillance program was initiated at Leiden University Medical Center with annual MRI and optional endoscopic ultrasound. Data were collected on the resection rate of screen-detected tumors and on survival. The Kaplan-Meier method and a parametric cure model were used to analyze and compare survival. Based on the surveillance and survival data from the screening program, a state-transition model was constructed to estimate lifelong outcomes., Results: A total of 347 mutation carriers participated in the surveillance program. PDAC was detected in 31 patients (8.9%) and the tumor could be resected in 22 patients (71.0%). Long-term cure among patients with resected PDAC was estimated at 47.1% (p < 0.001). The surveillance program was estimated to reduce mortality from PDAC by 12.1% and increase average life expectancy by 2.10 years. Lifelong costs increased by €13,900 per patient, with a cost-utility ratio of €14,000 per quality-adjusted life year gained. For annual surveillance to have an acceptable cost-effectiveness in other settings, lifetime PDAC risk needs to be 10% or higher., Conclusion: The tumor could be resected in most patients with a screen-detected PDAC. These patients had considerably better survival and as a result annual surveillance was found to be cost-effective., (© 2023 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.)
- Published
- 2023
- Full Text
- View/download PDF
19. Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Prospective Follow-Up.
- Author
-
Klatte DCF, Boekestijn B, Wasser MNJM, Feshtali Shahbazi S, Ibrahim IS, Mieog JSD, Luelmo SAC, Morreau H, Potjer TP, Inderson A, Boonstra JJ, Dekker FW, Vasen HFA, van Hooft JE, Bonsing BA, and van Leerdam ME
- Subjects
- Aged, Cyclin-Dependent Kinase Inhibitor p16 genetics, Early Detection of Cancer methods, Follow-Up Studies, Germ Cells pathology, Humans, Middle Aged, Prospective Studies, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal diagnostic imaging, Carcinoma, Pancreatic Ductal epidemiology, Carcinoma, Pancreatic Ductal genetics, Pancreatic Neoplasms diagnostic imaging, Pancreatic Neoplasms epidemiology, Pancreatic Neoplasms genetics
- Abstract
Purpose: Pancreatic cancer surveillance in high-risk individuals may lead to detection of pancreatic ductal adenocarcinoma (PDAC) at an earlier stage and with improved survival. This study evaluated the yield and outcomes of 20 years of prospective surveillance in a large cohort of individuals with germline pathogenic variants (PVs) in CDKN2A ., Methods: Prospectively collected data were analyzed from individuals participating in pancreatic cancer surveillance. Surveillance consisted of annual magnetic resonance imaging with magnetic resonance cholangiopancreatography and optional endoscopic ultrasound., Results: Three hundred forty-seven germline PV carriers participated in surveillance and were followed for a median of 5.6 (interquartile range 2.3-9.9) years. A total of 36 cases of PDAC were diagnosed in 31 (8.9%) patients at a median age of 60.4 (interquartile range 51.3-64.1) years. The cumulative incidence of primary PDAC was 20.7% by age 70 years. Five carriers (5 of 31; 16.1%) were diagnosed with a second primary PDAC. Thirty (83.3%) of 36 PDACs were considered resectable at the time of imaging. Twelve cases (12 of 36; 33.3%) presented with stage I disease. The median survival after diagnosis of primary PDAC was 26.8 months, and the 5-year survival rate was 32.4% (95% CI, 19.1 to 54.8). Individuals with primary PDAC who underwent resection (22 of 31; 71.0%) had an overall 5-year survival rate of 44.1% (95% CI, 27.2 to 71.3). Nine (2.6%; 9 of 347) individuals underwent surgery for a suspected malignant lesion, which proved to not be PDAC, and this included five lesions with low-grade dysplasia., Conclusion: This long-term surveillance study demonstrates a high incidence of PDAC in carriers of a PV in CDKN2A . This provides evidence that surveillance in such a high-risk population leads to detection of early-stage PDAC with improved resectability and survival.
- Published
- 2022
- Full Text
- View/download PDF
20. Feasibility of Velocity-Selective Arterial Spin Labeling in Breast Cancer Patients for Noncontrast-Enhanced Perfusion Imaging.
- Author
-
Franklin SL, Voormolen N, Bones IK, Korteweg T, Wasser MNJM, Dankers HG, Cohen D, van Stralen M, Bos C, and van Osch MJP
- Subjects
- Feasibility Studies, Female, Humans, Perfusion Imaging, Prospective Studies, Spin Labels, Breast Neoplasms diagnostic imaging
- Abstract
Background: Dynamic contrast-enhanced (DCE) MRI is the most sensitive method for detection of breast cancer. However, due to high costs and retention of intravenously injected gadolinium-based contrast agent, screening with DCE-MRI is only recommended for patients who are at high risk for developing breast cancer. Thus, a noncontrast-enhanced alternative to DCE is desirable., Purpose: To investigate whether velocity selective arterial spin labeling (VS-ASL) can be used to identify increased perfusion and vascularity within breast lesions compared to surrounding tissue., Study Type: Prospective., Population: Eight breast cancer patients., Field Strength/sequence: A 3 T; VS-ASL with multislice single-shot gradient-echo echo-planar-imaging readout., Assessment: VS-ASL scans were independently assessed by three radiologists, with 3-25 years of experience in breast radiology. Scans were scored on lesion visibility and artifacts, based on a 3-point Likert scale. A score of 1 corresponded to "lesions being distinguishable from background" (lesion visibility), and "no or few artifacts visible, artifacts can be distinguished from blood signal" (artifact score). A distinction was made between mass and nonmass lesions (based on BI-RADS lexicon), as assessed in the standard clinical exam., Statistical Tests: Intra-class correlation coefficient (ICC) for interobserver agreement., Results: The ICC was 0.77 for lesion visibility and 0.84 for the artifact score. Overall, mass lesions had a mean score of 1.27 on lesion visibility and 1.53 on the artifact score. Nonmass lesions had a mean score of 2.11 on lesion visibility and 2.11 on the artifact score., Data Conclusion: We have demonstrated the technical feasibility of bilateral whole-breast perfusion imaging using VS-ASL in breast cancer patients., Evidence Level: 1 TECHNICAL EFFICACY: Stage 1., (© 2021 The Authors. Journal of Magnetic Resonance Imaging published by Wiley Periodicals LLC. on behalf of International Society for Magnetic Resonance in Medicine.)
- Published
- 2021
- Full Text
- View/download PDF
21. Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study.
- Author
-
Woei-A-Jin FJSH, Weijl NI, Burgmans MC, Fariña Sarasqueta A, van Wezel JT, Wasser MNJM, Coenraad MJ, Burggraaf J, and Osanto S
- Subjects
- Angiogenesis Inhibitors therapeutic use, Benzimidazoles, Female, Humans, Living Donors, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Placenta Growth Factor, Quinolones, Vascular Endothelial Growth Factor A, Carcinoma, Hepatocellular drug therapy, Liver Neoplasms drug therapy, Liver Transplantation
- Abstract
Background: Hepatocellular carcinoma (HCC) recurrence rates following locoregional treatment are high. As multireceptor tyrosine kinase inhibitors targeting vascular endothelial growth factor receptors (VEGFRs) are effective in advanced HCC, we assessed the efficacy and safety of neoadjuvant systemic treatment with dovitinib in early- and intermediate-stage HCC., Materials and Methods: Twenty-four patients with modified Child-Pugh class A early- and intermediate-stage HCC received neoadjuvant oral dovitinib 500 mg daily (5 days on/2 days off) for 4 weeks, followed by locoregional therapy. Primary endpoints were objective response rates and intratumoral blood flow changes. Secondary endpoints were safety, pharmacodynamical plasma markers of VEGFR-blockade, time to progression (TTP), and overall survival (OS)., Results: Modified RECIST overall response rate was 48%, including 13% complete remission, and despite dose reduction/interruption in 83% of patients, intratumoral perfusion index decreased significantly. Grade 3-4 adverse events, most frequently (on-target) hypertension (54%), fatigue (25%), and thrombocytopenia (21%), occurred in 88% of patients. Plasma VEGF-A, VEGF-D, and placental growth factor increased significantly, whereas sTie-2 decreased, consistent with VEGFR-blockade. Following neoadjuvant dovitinib, all patients could proceed to their original planned locoregional treatment. No delayed toxicity occurred. Seven patients (three early, four intermediate stage) underwent orthotopic liver transplant after median 11.4 months. Censoring at transplantation, median TTP and OS were 16.8 and 34.8 months respectively; median cancer-specific survival was not reached., Conclusion: Already after a short 4-week dovitinib treatment period, intratumoral blood flow reduction and modest antitumor responses were observed. Although these results support use of systemic neoadjuvant strategies, the poor tolerability indicates that dovitinib dose adaptations are required in HCC., Implications for Practice: Orthotopic liver transplantation may cure early and intermediate-stage hepatocellular carcinoma. Considering the expected waiting time >6 months because of donor liver scarcity, there is an unmet need for effective neoadjuvant downsizing strategies. Angiogenesis inhibition by dovitinib does not negatively affect subsequent invasive procedures, is safe to administer immediately before locoregional therapy, and may provide a novel treatment approach to improve patient outcomes if tolerability in patients with hepatocellular carcinoma can be improved by therapeutic drug monitoring and personalized dosing., (© 2021 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.)
- Published
- 2021
- Full Text
- View/download PDF
22. Systematic approach towards reliable estimation of abdominal aortic aneurysm size by ultrasound imaging and CT.
- Author
-
Tomee SM, Meijer CA, Kies DA, le Cessie S, Wasser MNJM, Golledge J, Hamming JF, and Lindeman JHN
- Subjects
- Aorta, Abdominal diagnostic imaging, Clinical Trials as Topic, Humans, Observer Variation, Reproducibility of Results, Tomography, X-Ray Computed, Ultrasonography, Aortic Aneurysm, Abdominal diagnostic imaging
- Abstract
Background: The management of abdominal aortic aneurysm (AAA) is fully dictated by AAA size, but there are no uniform measurement guidelines, and systematic differences exist between ultrasound- and CT-based size estimation. The aim of this study was to devise a uniform ultrasound acquisition and measurement protocol, and to test whether harmonization of ultrasound and CT readings is feasible., Methods: A literature review was undertaken to evaluate evidence for ultrasound-based measurement of AAA. A protocol for measuring AAA was then developed, and intraobserver and interobserver reproducibility was tested. Finally, agreement between ultrasound readings and CT-based AAA diameters was evaluated. This was an observational study of patients with a small AAA who participated in two pharmaceutical intervention trials., Results: Based on a literature review, an ultrasound acquisition and reading protocol was devised. Evaluation of the protocol showed an intraobserver repeatability of 1.6 mm (2s.d.) and an interobserver intraclass correlation coefficient (ICC) of 0.97. Comparison of protocolled ultrasound readings and local CT readings indicated a good correlation (r = 0.81), but a systematic +4.1-mm difference for CT. Harmonized size readings for ultrasound imaging and CT increased the correlation (r = 0.91) and reduced the systematic difference to +1.8 mm by CT. Interobserver reproducibility of protocolized CT measurements showed an ICC of 0.94 for the inner-to-inner method and 0.96 for the outer-to-outer method., Conclusion: The absence of harmonized size acquisition and reading guidelines results in overtreatment and undertreatment of patients with AAA. This can be avoided by the implementation of standardized ultrasound acquisition and a harmonized reading protocol for ultrasound- and CT-based readings., (© The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
23. Magnetic Resonance Thrombus Imaging to Differentiate Acute from Chronic Portal Vein Thrombosis.
- Author
-
van Dam LF, Klok FA, Tushuizen ME, Ageno W, Darwish Murad S, van Haren GR, Huisman MV, Lauw MN, Iglesias Del Sol A, Wasser MNJM, Willink Y, and Kroft LJM
- Abstract
Introduction Timely diagnosis and treatment of portal vein thrombosis (PVT) is crucial to prevent morbidity and mortality. However, current imaging tests cannot always accurately differentiate acute from chronic (nonocclusive) PVT. Magnetic resonance noncontrast thrombus imaging (MR-NCTI) has been shown to accurately differentiate acute from chronic venous thrombosis at other locations and may also be of value in the diagnostic management of PVT. This study describes the first phase of the Rhea study (NTR 7061). Our aim was to select and optimize MR-NCTI sequences that would be accurate for differentiation of acute from chronic PVT. Study Design The literature was searched for different MRI sequences for portal vein and acute thrombosis imaging. The most promising sequences were tested in a healthy volunteer followed by one patient with acute PVT and two patients with chronic PVT, all diagnosed on (repetitive) contrast-enhanced computed tomography (CT) venography to optimize the MR-NCTI sequences. All images were evaluated by an expert panel. Results Several MR-NCTI sequences were identified and tested. Differentiation of acute from chronic PVT was achieved with 3D T1 TFE (three-dimensional T1 turbo field echo) and 3D T1 Dixon FFE (three-dimensional T1 fast field echo) sequences with best image quality. The expert panel was able to confirm the diagnosis of acute PVT on the combined two MR-NCTI sequences and to exclude acute PVT in the two patients with chronic PVT. Conclusion Using 3D T1 TFE and 3D T1 Dixon FFE sequences, we were able to distinguish acute from chronic PVT. This clinical relevant finding will be elucidated in clinical studies to establish their test performance., Competing Interests: Conflict of Interest None declared.
- Published
- 2020
- Full Text
- View/download PDF
24. Long-term Evaluation of Allogeneic Bone Marrow-derived Mesenchymal Stromal Cell Therapy for Crohn's Disease Perianal Fistulas.
- Author
-
Barnhoorn MC, Wasser MNJM, Roelofs H, Maljaars PWJ, Molendijk I, Bonsing BA, Oosten LEM, Dijkstra G, van der Woude CJ, Roelen DL, Zwaginga JJ, Verspaget HW, Fibbe WE, Hommes DW, Peeters KCMJ, and van der Meulen-de Jong AE
- Subjects
- Adult, Double-Blind Method, Female, Follow-Up Studies, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Rectal Fistula diagnostic imaging, Rectal Fistula etiology, Time Factors, Treatment Outcome, Crohn Disease complications, Mesenchymal Stem Cell Transplantation methods, Rectal Fistula therapy
- Abstract
Background and Aims: The long-term safety and efficacy of allogeneic bone marrow-derived mesenchymal stromal cell [bmMSC] therapy in perianal Crohn's disease [CD] fistulas is unknown. We aimed to provide a 4-year clinical evaluation of allogeneic bmMSC treatment of perianal CD fistulas., Methods: A double-blind dose-finding study for local bmMSC therapy in 21 patients with refractory perianal fistulising Crohn's disease was performed at the Leiden University Medical Center in 2012-2014. All patients treated with bmMSCs [1 x 107 bmMSCs cohort 1, n = 5; 3 × 107 bmMSCs cohort 2, n = 5; 9 × 107 bmMSCs cohort 3, n = 5] were invited for a 4-year evaluation. Clinical events were registered, fistula closure was evaluated, and anti-human leukocyte antigen [HLA] antibodies were assessed. Patients were also asked to undergo a pelvic magnetic resonance imaging [MRI] and rectoscopy., Results: Thirteen out of 15 patients [87%] treated with bmMSCs were available for long-term follow-up. Two non-MSC related malignancies were observed. No serious adverse events thought to be related to bmMSC therapy were found. In cohort 2 [n = 4], all fistulas were closed 4 years after bmMSC therapy. In cohort 1 [n = 4] 63%, and in cohort 3 [n = 5] 43%, of the fistulas were closed, respectively. In none of the patients anti-HLA antibodies could be detected 24 weeks and 4 years after therapy. Pelvic MRI showed significantly smaller fistula tracts after 4 years., Conclusions: Allogeneic bmMSC therapy for CD-associated perianal fistulas is also in the long-term a safe therapy. In bmMSC-treated patients, fistulas with closure at Week 24 were still closed after 4 years., (© The Author(s) 2019. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.